PALO ALTO, Calif. & LONDON--(BUSINESS WIRE)--Anacor Pharmaceuticals and GlaxoSmithKline PLC (GSK) today announced that GSK has exercised its option to obtain an exclusive licence to develop and commercialise GSK2251052 (GSK ‘052), formerly known as AN3365. GSK ‘052 is a novel, systemic antibiotic derived from Anacor’s boron chemistry platform.
